Hyperbilirubinemia during Quinupristin‐Dalfopristin Therapy in Liver Transplant Recipients: Correlation with Available Liver Biopsy Results

• DOI: 10.1592/phco.21.7.661.34580
• Publication Date: 2004-06-11T13:55:05Z
• Authors: Peter K. Linden; François Bompart; Sharon Gray; George H. Talbot
• Keywords: Dalfopristin; Quinupristin

Study Objective. To review the liver histopathology in transplant recipients who developed hyperbilirubinemia during therapy with quinupristin‐dalfopristin, a new streptogramin antibiotic, and to ascertain whether objective histologic evidence of adverse drug effect could be correlated serum bilirubin levels. Design. Retrospective analysis. Setting. University Pittsburgh Medical Center. Patients. From database 34 received quinupristin‐dalfopristin for vancomycin‐resistant Enterococcus faecium infection were prospectively enrolled multicenter, open‐label, emergency‐use protocol, data subset 25 patients underwent one or more biopsies reviewed this study. Interventions. Quinupristin‐dalfopristin was administered intravenously at 7.5 mg/kg every 8 hours. Available levels from before, during, 1 week after tabulated. Liver biopsy results obtained within before retrospectively reviewed. Histopathologic characterized level. Measurements Main Results. Cholestatic changes already present 15 17 therapy. During therapy, most common findings 40 (25 patients) cholestasis (33 biopsies), acute rejection (10), periportal inflammation (8). There no drug‐specific histopathologic injury. Conclusion. Hyperbilirubinemia these likely multifactorial frequently due sepsis prior graft